Jorge C Blanco
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$5.4MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $5.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 16, 2024 | NIH | STTR Phase I Inducible HMGB1 antagonist for viral-induced acute lung injury. | $63K | SIGMOVIR BIOSYSTEMS, INC. |
| Aug 12, 2024 | NIH | STTR Phase I Inducible HMGB1 antagonist for viral-induced acute lung injury. | $488K | SIGMOVIR BIOSYSTEMS, INC. |
| Jun 27, 2024 | NIH | STTR Phase I Inducible HMGB1 antagonist for viral-induced acute lung injury. | $30K | SIGMOVIR BIOSYSTEMS, INC. |
| Aug 31, 2023 | NIH | STTR Phase I Inducible HMGB1 antagonist for viral-induced acute lung injury. | $488K | SIGMOVIR BIOSYSTEMS, INC. |
| Feb 12, 2021 | NIH | SBIR Phase II Development of VLP vaccine for RSV | $1.0M | SIGMOVIR BIOSYSTEMS, INC. |
| May 21, 2020 | NIH | SBIR Phase II Development of VLP vaccine for RSV | $477K | SIGMOVIR BIOSYSTEMS, INC. |
| Mar 4, 2020 | NIH | SBIR Phase II Development of VLP vaccine for RSV | $1.0M | SIGMOVIR BIOSYSTEMS, INC. |
| Jul 15, 2017 | NIH | STTR Phase II Development of VLP vaccine for RSV | $934K | SIGMOVIR BIOSYSTEMS, INC. |
| Aug 18, 2016 | NIH | STTR Phase II Development of VLP vaccine for RSV | $934K | SIGMOVIR BIOSYSTEMS, INC. |
Peer ranks
Federal funding#237
Awards as PI#151
Patents#273
Companies
- SIGMOVIR BIOSYSTEMS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.